The US HIV Diagnostics Market: Driven by Universal Screening Directives, Pre-Exposure Prophylaxis (PrEP) Monitoring, and the Goal of Eradicating HIV Transmission
The US HIV Diagnostics Market is a mature yet dynamically evolving sector, critically driven by ambitious national public health goals to end the HIV epidemic and the widespread adoption of universal screening guidelines, making it a vital discussion point for public health strategy and clinical policy. The primary market driver is the shift towards opt-out, routine HIV screening in healthcare settings, as recommended by the CDC and the US Preventive Services Task Force, ensuring that more people are diagnosed early and linked to care. This aggressive screening strategy is essential because early diagnosis drastically improves patient outcomes and, crucially, prevents onward transmission, as effective antiretroviral therapy (ART) makes the virus virtually untransmittable. The discussion should highlight the growth of Point-of-Care (POC) rapid testing technologies, which allow for quick, non-laboratory-based…